目的 探讨腹膜后囊性淋巴管瘤的CT诊断价值和治疗方法。方法 回顾性分析2004年6月至2010年5月期间我院收治的5例经病理检查证实的腹膜后囊性淋巴管瘤患者的临床表现、CT影像特征、手术治疗及术后随访的资料。结果 5例患者术前CT均诊断为囊性淋巴管瘤，均行手术完整切除肿瘤，术后病理结果均证实为囊性淋巴管瘤。术后7 d顺利出院，随访3个月～6年均无复发。结论 CT对腹膜后囊性淋巴管瘤的诊断具有重要意义，手术完整切除整个囊壁是治疗及预防术后复发的最好方法。
目的探讨胃底贲门癌患者行全胃切除术后消化道的重建方式。 方法总结我院1999年3月至2002年4月间采用经腹全胃切除保留幽门环间置空肠重建消化道手术的16例胃底贲门癌患者的临床资料。 结果无一例手术死亡， 无吻合口漏及狭窄， 全组患者均治愈出院。 术后半年每餐进食200～300 g， 每日3～4次， 其中蛋白质1 g/（kg·d）， 总热量为2 300～3 000 kcal，餐后无胸骨后灼痛，无胆汁返流现象及排空障碍。结论严格掌握手术适应证，保留幽门环间置空肠重建消化道能起到较好的效果。
Objective To evaluate whether jejunal interposition pouch (JIP) reconstruction is an ideal procedure of digestive tract reconstruction after total gastrectomy. Methods Ninetyfour patients after total gastrectomy had randomly divided into two groups, JIP group 42 cases and RouxenY pouch (RYP) group 52 cases. The gastrointestinal function improvement in body weight and nutritional parameters (serum albumin, hemoglobin level, and serum protein) were compared 1 year after surgery for the two groups. Results The nutritional condition of JIP group and RYP group after operation had improved (P＜0.01); and the condition of JIP group with fewer symptom problems demonstrated much more better than standard RYP group （P＜0.01）. Conclusion JIP that could obtain partly compensatory function after total gastrectomy is an ideal reconstruction.
Objective To assess the effect of astragaulus membranaceus in the treatment of pulmonary tuberculosis. Methods Through applying the methods provided by the Cochrane Collaboration, the randomized controlled trials (RCTs) or quasi-RCTs of astragaulus membranaceus in the treatment of pulmonary tuberculosis were searched in The Cochrane Library (Issue 3, 2010), CNKI (1991 to May 2010), VIP (1989 to May 2010), EMbase (1981 to May 2010), and PubMed (1981 to May 2010). Two reviewers independently screened the included studies, extracted the data, assessed the quality, and cross checked then. The RevMan 5.0 software was used to conduct meta-analyses. Results Twelve RCTs involving 1 054 patients were included. All trials were tested in the mainland China. The results of meta-analyses showed that: a) The astragaulus membranaceus could assist the conventional drug to cure pulmonary tuberculosis, promote sputum negative conversion, focal absorption and cavity reduction in lung; b) The astragaulus membranaceus could reduce the adverse reactions of the conventional drug; c) The astragaulus membranaceus combined with the conventional drug could improve the patients’ symptoms and signs; and d) The astragaulus membranaceus combined with the conventional drug could reduce the bacterial relapse rates in follow-up after treatment. Conclusion The current evidence shows that the astragaulus membranaceus has some effects and is relatively safe to treat pulmonary tuberculosis. However, it is far from enough to recommend astragaulus membranaceus as a conventional adjuvant therapy for pulmonary tuberculosis because of no sufficient evidence obtained from this study for its small sample and low methodology quality. Therefore, more double-blind multi-center RCTs with high quality, large sample, and adequate follow up are required for further verification.